Cargando…
Patient Reported Outcome (PRO) assessment in epilepsy: a review of epilepsy-specific PROs according to the Food and Drug Administration (FDA) regulatory requirements
Despite collection of patient reported outcome (PRO) data in clinical trials of antiepileptic drugs (AEDs), PRO results are not being routinely reported on European Medicines Agency (EMA) and Food and Drug Administration (FDA) product labels. This review aimed to evaluate epilepsy-specific PRO instr...
Autores principales: | Nixon, Annabel, Kerr, Cicely, Breheny, Katie, Wild, Diane |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3606363/ https://www.ncbi.nlm.nih.gov/pubmed/23497117 http://dx.doi.org/10.1186/1477-7525-11-38 |
Ejemplares similares
-
Interpreting change from patient reported outcome (PRO) endpoints: patient global ratings of concept versus patient global ratings of change, a case study among osteoporosis patients
por: Nixon, Annabel, et al.
Publicado: (2016) -
The Administration of Luminal in Epilepsy
Publicado: (1927) -
The FDA guidance for industry on PROs: the point of view of a pharmaceutical company
por: Arpinelli, Fabio, et al.
Publicado: (2006) -
Epilepsy and the Administration of Bromide of Potassium
por: Rogers, G. Goddard
Publicado: (1865) -
Information to Improve Public Perceptions of the Food and Drug Administration (FDA’s) Tobacco Regulatory Role
por: Osman, Amira, et al.
Publicado: (2018)